Affiliation:
1. Zhejiang University
2. Zhejiang Chinese Medical University
3. Hangzhou Third People’s Hospital, Zhejiang University School of Medicine, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University
Abstract
Abstract
Background
Recent cross-sectional analyses have disclosed associations between gut microbiota diversity and alopecia areata (AA). However, the definitive causal influence of gut microbiota on AA remains undetermined.
Methods
To probe the potential causal association between gut microbiota and AA, we leveraged data from Genome-wide association studies (GWAS) conducted by both the MiBioGen and FinnGen consortiums. The dataset included information on gut microbiota (n = 13,266) and AA (n = 211,428), extracted from earlier observational studies. We applied five statistical techniques in our Mendelian randomization (MR) analysis to infer the causality between gut microbiota and AA. Conversely, we undertook a reverse MR analysis to ascertain whether AA causally impacts gut microbiota. The validity of the MR analysis was evaluated via sensitivity analysis.
Results
The IVW assessment implied a protective influence against AA from Butyricimonas (OR = 0.37, 95% CI: 0.18–0.77, p = 0.01), Enterorhabdus (OR = 0.40, 95% CI: 0.16–0.95, p = 0.04), Eubacterium (xylanophilum group) (OR = 0.36, 95% CI: 0.15–0.84, p = 0.02), and Phascolarctobacterium (OR = 0.37, 95% CI: 0.15–0.91, p = 0.03). In contrast, Ruminococcaceae UCG003 emerged as a risk factor for AA (OR = 2.79, 95% CI: 1.27–6.14, p = 0.01). Our reverse MR exploration did not discern any statistically significant causal association between AA and gut microbiota. Similarly, no significant heterogeneity of IVs or horizontal pleiotropy was observed.
Conclusions
This current study offers compelling evidence for a probable causality between certain gut microbiota and AA, thus providing vital insights into its pathogenesis and potential preventative and therapeutic approaches.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Baricitinib in Alopecia Areata;Messenger A;N Engl J Med,2022
2. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study;King B;J Am Acad Dermatol,2021
3. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis;Lee HH;J Am Acad Dermatol,2020
4. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management;Zhou C;Clin Rev Allergy Immunol,2021
5. Gut-microbiota-targeted diets modulate human immune status;Wastyk HC;Cell,2021